检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王德俊[1,2] 于灵灵[1,2] 孙东良[1,2]
机构地区:[1]河北联合大学附属医院 [2]唐海县医院内科二科,河北唐海063200
出 处:《中国医药导报》2012年第20期60-61,64,共3页China Medical Herald
摘 要:目的分析联合应用氟桂利嗪与低分子肝素治疗频发性短暂脑缺血发作的疗效。方法选取146例频发性短暂脑缺血发作患者,按治疗方案不同分为两组:对照组,予以低分子肝素治疗,共77例;研究组,在低分子肝素基础上加用氟桂利嗪,共69例。治疗2周后,分别进行临床疗效及不良反应比较。结果与对照组比较,研究组总有效率、显效率明显较高(P<0.05),两组治疗后全血黏度(低切)、全血黏度(高切)、血浆黏度、纤维蛋白原含量较治疗前明显下降(P<0.05),但治疗后研究组较对照组明显改善(P<0.05)。研究组的血细胞减少、皮疹、头痛、肝功能异常等不良反应较对照组差异无统计学意义(P>0.05)。结论应用氟桂利嗪与低分子肝素治疗频发性短暂脑缺血发作疗效可靠,不良反应少。Objective To analyze the efficacy of the combination of Flunarizine and low molecular weight heparin for the frequency of recurrent transient ischemic attacks (TIA). Methods 146 cases of frequent TIA patients were randomly divided into 2 groups according to the treatment program. 77 patients of control group were given low molecular weight heparin, 69 patients of control group were treated with Flunarizine on the basis of low molecular weight heparin. The clinical effica- cy and adverse reactions of two groups after treatment were compared. Results Compared with the control group, the utility and excellence rates of the study group were significantly higher (P 〈 0.05). Whole blood viscosity (low cut), whole blood viscosity (high shear), plasma viscosity, fibrinogen in the two groups after treatment were decreased significantly than before treatment (P 〈 0.05), but the study group were improved more significantly than the control group (P 〈 0.05). The adverse reactions of pancytopenia, rash, headache, abnormal liver function in tow groups were not significant different (P 〉 0.05). Conclusion The application of Flunarizine combined with low molecular weight heparin for the frequent TIA is reliable and has fewer adverse reactions.
关 键 词:氟桂利嗪 低分子肝素 短暂脑缺血发作 疗效 不良反应
分 类 号:R742.3[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3